A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity
Latest Information Update: 04 Mar 2026
At a glance
- Drugs NNC6989 0001 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
Most Recent Events
- 04 Mar 2026 New trial record